Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Oswaldo Cruz Foundation (Fiocruz) is a leading institution of science and a public health in Latin America. The new online knowledge hub launched on 3rd December 2019 and feature virtual courses, information and news about the Foundation.

TGHN team

The Fiocruz Knowledge Hub is an online sharing space, which aims to strengthen networks and increase Fiocruz's international presence, contributing to improve regional and global public health research capacities.

Bonny Baker who leads The Global Health Network regional programs and Gustavo Matta Researcher and Coordinator of the Zika Social Sciences Network at Fiocruz introduced the Fiocruz Hub at the International Seminar of the Fiocruz Internationalization Program in Rio de Janeiro today.

Fiocruz's virtual space is the result of partnership signed on July between the Foundation and the University of Oxford, responsible for the Global Health Network. Fiocruz is the most prominent Institution of Science and Technology in Health in Latin America, with a large expertise in teaching and researching, and solid history of cooperation with Latin American and Portuguese speaking African countries.

With the new space, Fiocruz online courses will be available for The Global Health Network community. Fiocruz Virtual Campus have already qualified over 1.8 million Brazilian health professionals, in areas such as Yellow Fever, Zika, maternal care, public systems and others. The knowledge hub will also be updated with publications with the latest research results, as well as information and news about Fiocruz.

Similar stories

RECOVERY trial finds Regeneron’s monoclonal antibody combination reduces deaths for hospitalised COVID-19 patients who have not mounted their own immune response

The Randomised Evaluation of COVID-19 Therapy (RECOVERY) trial has demonstrated that the investigational antibody combination developed by Regeneron reduces the risk of death when given to patients hospitalised with severe COVID-19 who have not mounted a natural antibody response of their own.

Professors Peter Horby and Guy Thwaites recognised in Queen’s Birthday Honours

The pioneering work of members of the University of Oxford has been recognised in The Queen's Birthday Honours List. The honorands include Professor Peter Horby and six researchers that have played key roles in leading the University’s response to the Coronavirus pandemic, from the development of new vaccines to the discovery of new drug treatments. Professor Guy Thwaites is appointed a Member of the Order of the British Empire.

RECOVERY trial finds aspirin does not improve survival for patients hospitalised with COVID-19

The RECOVERY trial was established as a randomised clinical trial to test a range of potential treatments for patients hospitalised with COVID-19. Patients with COVID-19 are at increased risk of blood clots forming in their blood vessels, particularly in the lungs. Between November 2020 and March 2021, the RECOVERY trial included nearly 15,000 patients hospitalised with COVID-19 in an assessment of the effects of aspirin, which is widely used to reduce blood clotting in other diseases. There was no significant difference in the primary endpoint of 28-day mortality

The COVID-19 International Modelling Consortium (CoMo Consortium) enters a new phase

Created in March 2020 to assist policymakers to make use of existing evidence in mathematical and epidemiological models to inform strategies for minimising the impact of COVID-19, the CoMo Consortium brings together mathematical modellers, epidemiologists, health economists and public health experts from more than 40 countries across Africa, Asia and South and North America.

New Pandemic Sciences Centre at the University of Oxford

The University of Oxford announces the launch of a centre of global research collaboration and excellence, the Pandemic Sciences Centre. The need for partnership between academic excellence, industry and public health organisations is one of the key lessons learned from the coronavirus pandemic. This centre will unite disciplines, and sectors, to build agile, equitable partnerships that can tackle complex problems and respond to pandemic threats at any time.

RECOVERY trial named David Sackett Trial of the Year 2020

The RECOVERY trial has been named David Sackett Trial of the Year by the Society for Clinical Trials. The award was presented today at the Society for Clinical Trials’ 42nd Annual Meeting.